Readnour Robin Shane

AN2 Therapeutics, Inc. · Director

Readnour Robin Shane is listed in filings as Director at AN2 Therapeutics, Inc.. This profile follows SEC Form 4 activity through Mar 23, 2026, including purchase activity. Recent filings connect the profile to AN2 Therapeutics, Inc. (ANTX). The current snapshot covers public activity from Jun 21, 2024 to Mar 23, 2026. Reported amounts are shown as $129.0K to $28.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.

Data sources and methodology

Latest Trades

CompanyValueActionPriceLast Price
AN2 Therapeutics, Inc.ANTX$7.5k5k sharesBuyDec 10, 2024$1.49$4.46
AN2 Therapeutics, Inc.ANTX$7.5k5k sharesBuyDec 10, 2024$1.49$4.46